Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective...
(Source: Minerva Neurosciences Inc) Preliminary results provide additional support for progression of MIN-202 into next stage of clinical development. Minerva developing MIN-202 in collaboration with...
View ArticleMinerva Neurosciences Announces Favorable Top Line Results From MIN-202 Phase...
(Source: Minerva Neurosciences Inc) , (GLOBE NEWSWIRE) -- (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders,...
View ArticleFurther data on selexipag (Uptravi) to be presented at CHEST 2015 Congress...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 22 October 2015 - Actelion Ltd (SIX: ATLN) today announced that further key data from the pivotal Phase III GRIPHON study with the investigational drug...
View ArticleMinerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective...
Preliminary results provide additional support for progression of MIN-202 into next stage of clinical development. Minerva developing MIN-202 in collaboration with Janssen. WALTHAM, Mass., Jan. 21,...
View ArticleActelion's novel antibiotic cadazolid receives US FDA Qualified Infectious...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 27 February 2014 - Actelion Ltd (SIX: ATLN) today announced that the US Food and Drug Administration (FDA) has designated cadazolid as both a...
View ArticleMinerva Neurosciences Reports First Quarter 2016 Financial Results and...
Positive top line results of trials with MIN-202 highlight first quarter Last patient visits completed in trials with MIN-101 and MIN-117; data expected in second quarter WALTHAM, Mass., May 03, 2016...
View ArticleActelion emphasizes commitment to advance research and care in rare diseases...
(Source: Actelion Ltd) 'Patient Voice - Join us in making the voice of rare diseases heard.' This is the theme of Rare Disease Day 2016 - and a cause for Actelion to emphasize its long-term commitment...
View ArticleActelion delivers outstanding 2014 results (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 February 2015- Actelion Ltd (SIX: ATLN) today announced its results for the full year 2014. OPERATING HIGHLIGHTS Opsumit - Sales of CHF 180...
View ArticleActelion announces first quarter 2014 financial results (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 17 April 2014 - Actelion Ltd (SIX: ATLN) today announced financial results for the first three months of 2014. OPERATING HIGHLIGHTS Opsumit -...
View ArticleEisai and Purdue Pharma Enter Worldwide Collaboration to Develop and...
WOODCLIFF LAKE, N.J. and STAMFORD, Conn., Aug. 31, 2015 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered...
View ArticleAdditional data on selexipag (Uptravi) and macitentan (Opsumit) to be...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 27 August 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag...
View ArticleActelion delivers strong half year operational and financial results...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 22 July 2014 - Actelion Ltd (SIX: ATLN) today announced its results for the first half of 2014. OPERATING HIGHLIGHTS Opsumit - US launch momentum...
View ArticleActelion provides an update on the bosentan study - COMPASS 2 (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 17 March 2014 - Actelion Ltd (SIX: ATLN) today announced the results of COMPASS-2, a Phase IV, prospective, randomized, double-blind,...
View ArticleActelion presents outstanding 2015 results - Company transformation...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 09 February 2016- Actelion Ltd (SIX: ATLN) today announced its results for the full year 2015. OPERATING HIGHLIGHTS Opsumit - Strong, sustained...
View ArticleActelion is granted marketing authorization for Uptravi (selexipag) in...
(Source: Nippon Shinyaku Co Ltd) May 17. 2016 ・Marketing authorization granted by European Commission on 12 May 2016 ・First European Union (EU) market introduction to commence in the near future...
View ArticleNew data supporting gradual up-titration of ponesimod to mitigate first-dose...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 25 June 2015 - Actelion Ltd (SIX: ATLN) today announced that data supporting a gradual up-titration dose regimen of ponesimod will be presented at the...
View ArticleThe New England Journal of Medicine publishes "Selexipag for the treatment of...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 23 December 2015 - Actelion (SIX: ATLN) announced today that the New England Journal of Medicine (NEJM) has published the results of the oral, selective...
View ArticleFurther data on selexipag (Uptravi) and macitentan (Opsumit) to be presented...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 13 May 2015 - Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag...
View ArticleSelexipag (Uptravi) long-term outcome data in pulmonary arterial hypertension...
(Source: Actelion Ltd) Selexipag significantly reduced the risk of a morbidity/mortality event by 40% versus placebo (p Selexipag improved long-term outcomes in an investigational trial of patients...
View ArticleActelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki...
(Source: Actelion Ltd) SAVANNAH, UNITED STATES OF AMERICA AND ALLSCHWIL, SWITZERLAND - 05 September 2015 - Actelion Ltd (SIX: ATLN) today announced that its Chief Scientific Officer and Member of the...
View Article